Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer

Mark Doherty, Vincent C. Tam, Mairéad G. McNamara, Raymond Woo-Jun Jang, David W. Hedley, Eric X. Chen, Neesha C. Dhani, Patricia A. Tang, Hao‐Wen Sim, Grainne M. O’Kane, Stephanie DeLuca, Lisa Wang, Theresa Pedutem, Jennifer J. Knox